Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: posaconazole Clear all
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 7, 2026, 4:27 PM EDT
Completed No phase listed Observational

Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011
View directory record Official record
Conditions
Invasive Fungal Infection
Interventions
Isavuconazonium sulfate, Voriconazole, Posaconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
2,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 7, 2026, 4:27 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

NCT03530683
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
62
States / cities
Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Posaconazole in Crohn's Disease

NCT04966585
View directory record Official record
Conditions
Crohn Disease, CARD9 S12N Risk Allele
Interventions
Posaconazole Delayed Release Oral Tablet, Matching Placebo Tablet
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients

NCT01419678
View directory record Official record
Conditions
Lung Transplant Infection, Fungal Infection
Interventions
collection of blood samples for PK testing
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional

Imetelstat Combinations in Relapsed AML

NCT07320235
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia
Interventions
Imetelstat, Azacitidine, Venetoclax
Drug
Lead sponsor
Douglas Tremblay
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

NCT07283094
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Venetoclax, FHD-286
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Not yet recruiting Phase 1 Interventional

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

NCT07780565
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Interventions
Monzosertib, Posaconazole, Isavuconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

NCT06129734
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia
Interventions
Venetoclax, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226
View directory record Official record
Conditions
Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
Interventions
AZD3632, Posaconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Decatur, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers

NCT01984229
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alectinib, Posaconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

NCT04294641
View directory record Official record
Conditions
Chronic GVHD
Interventions
Ibrutinib, ECG, PFT's, CT, Steroid pulse (prednisone), Voriconazole, Posaconazole, Azithromycin, Montelukast, Budesonide, Beclomethasone, Filgrastim, Pegfilgrastim, Erythropoietin, Transfusions, Oral/Skin biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional

Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095

NCT00177749
View directory record Official record
Conditions
Fungal Infection
Interventions
Posaconazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 1 Interventional

Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children

NCT02358499
View directory record Official record
Conditions
Fungal Infections
Interventions
Posaconazole
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 1 Interventional

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

NCT01901172
View directory record Official record
Conditions
Neoplasms
Interventions
RO5503781, posaconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 7, 2026, 4:27 PM EDT
Not yet recruiting Phase 3 Interventional

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

NCT07261150
View directory record Official record
Conditions
Histoplasmosis
Interventions
LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC, WHO-recommended SOC Itraconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 1 Interventional

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

NCT07044544
View directory record Official record
Conditions
Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
G-CSF, Decitabine, Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

NCT01200355
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
micafungin, posaconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 7, 2026, 4:27 PM EDT
Recruiting Phase 2 Interventional

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

NCT04665037
View directory record Official record
Conditions
Invasive Fungal Infection
Interventions
Posaconazole IV 6 mg/kg, Posaconazole PFS 6 mg/kg
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

NCT00002446
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Posaconazole to Treat Invasive Fungal Infections

NCT00033982
View directory record Official record
Conditions
Granulomatous Disease, Chronic, Job's Syndrome, Infection
Interventions
Posaconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Kenilworth, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 7, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 7, 2026, 4:27 PM EDT